AbbVie 2013 Annual Report Download - page 156

Download and view the complete annual report

Please find page 156 of the 2013 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

2013 Outstanding Equity Awards at Fiscal Year-End
The following table summarizes the outstanding AbbVie equity awards held by the named
executive officers at year-end.
Option Awards(1)(2) Stock Awards(1)
Equity
Equity Incentive
Incentive Plan Awards:
Plan Awards: Market or
Market Number of Payout Value
Number of Number of Number of Value of Unearned of Unearned
Securities Securities Shares or Shares or Shares, Units Shares, Units
Underlying Underlying Units of Units of or Other or Other
Unexercised Unexercised Option Option Stock That Stock That Rights That Rights That
Options (#) Options (#) Exercise Expiration Have Not Have Not Have Not Have Not
Name Exercisable Unexercisable Price ($) Date Vested (#) Vested ($) Vested (#) Vested ($)
R. Gonzalez . . . . . 18,366 18,367(3) 24.2082 02/17/2021 13,067(3) $690,068
35,767 71,533(3) 29.2265 02/16/2022 39,600(3) 2,091,276
526,430(3) 35.8800 02/13/2023 257,720(3) 13,610,193
L. Schumacher . . . . 66,300 28.8628 02/14/2018 13,633(3) 719,959
38,940 28.1251 02/19/2019 29,466(3) 1,556,099
42,533 28.3122 02/18/2020 59,202(3) $3,126,458
19,166 19,167(3) 24.2082 02/17/2021 71,230(3) 3,761,656
26,600 53,200(3) 29.2265 02/16/2022
145,510(3) 35.8800 02/13/2023
8,928(3) 43.2100 02/19/2014
W. Chase ....... 8,495 24.0731 02/17/2015 4,500(3) 237,645
6,600 27.2940 02/15/2017 7,266(3) 383,717
25,500 28.8628 02/14/2018 44,401(3) 2,344,817
12,800 28.1251 02/19/2019 56,700(3) 2,994,327
13,400 28.3122 02/18/2020
12,667 6,333(3) 24.2082 02/17/2021
6,534 13,066(3) 29.2265 02/16/2022
115,830(3) 35.8800 02/13/2023
C. Alban ....... 30,533 15,267(3) 24.2082 02/17/2021 10,833(3) 572,091
16,034 32,066(3) 29.2265 02/16/2022 17,800(3) 940,018
115,830(3) 35.8800 02/13/2023 35,521(3) 1,875,864
56,700(3) 2,994,327
T. Richmond . . . . . 87,040(3) 35.8800 02/13/2023 10,000(3) 528,100
1,533(3)(4) 80,958
3,300(3)(5) 174,273
29,600(3) 1,563,176
42,610(3) 2,250,234
(1) When AbbVie separated from Abbott on January 1, 2013, outstanding Abbott equity awards generally
converted into adjusted awards based on Abbott common shares and AbbVie common stock (except to
the extent prohibited by local law or with respect to certain awards described below).
Holders of Abbott restricted shares or restricted stock units generally retained those awards and
received restricted stock or restricted stock units of AbbVie in an amount that reflected the distribution
to Abbott shareholders, except for Abbott restricted stock awards granted on December 1, 2012 that
converted in full into AbbVie restricted stock awards as of the Separation, as described in note (d) to
footnote (3) below. Such awards are subject to substantially the same terms, vesting conditions and
other restrictions that applied to the original Abbott awards immediately before the distribution.
Each Abbott stock option was converted into an adjusted Abbott stock option and an AbbVie stock
option, with adjustments to the stock option exercise prices that were intended to preserve the value of
the original Abbott award as measured immediately before and immediately after the distribution. Each
such adjusted Abbott stock option and AbbVie stock option is subject to substantially the same terms,
33